Regarding spironolactone, there is evidence to suggest that it may be protective in the COVID-19 setting by downregulating the androgen promoter of TMPRSS2 by its antiandrogenic actions and upregulating protease nexin 1 or serpin E2 (PN1), which in turn inhibits furin and plasmin, two of the processors of the spike protein [94]. This evidence concerns the gene TMPRSS2 and COVID-19.